Posted by Michael Wonder on 18 Dec 2018
Cipher Pharmaceuticals announces A-101 40% topical solution accepted for review by Health Canada
18 December 2018 - Cipher Pharmaceuticals today announced that its new drug submission for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses has been accepted for review by Health Canada.
Cipher acquired the exclusive Canadian rights to distribute and commercialise A-101 40% from Aclaris Therapeutics in April 2018.
A-101 40% is a U.S. FDA approved product indicated for the treatment of raised solar keratoses, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern. A-101 40% was approved by the FDA in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata.
